Format

Send to

Choose Destination
See comment in PubMed Commons below
J Am Soc Nephrol. 2004 Jan;15(1):142-7.

Timing of complications in percutaneous renal biopsy.

Author information

  • 1Section of Nephrology, Department of Medicine, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60607, USA. william_whittier@rush.edu

Abstract

Percutaneous renal biopsy (PRB) is a safe and effective tool in the diagnosis and management of renal disease; however, the optimal timing of observation after biopsy is not clearly established. With the use of real-time ultrasound guidance, PRB of native kidneys was performed in 750 adult patients at an academic institution by an attending nephrologist or fellow between June 1983 and June 2002. All patients were observed for 23 to 24 h after biopsy for the presence, severity, and timing of complications. Biopsy-related complications occurred in 98 (13%) patients; minor complications occurred in 50 (6.6%) patients, and major complications occurred in 48 (6.4%) patients. One (0.1%) patient died as a result of the biopsy. Multivariate analysis using logistic regression found only serum creatinine at baseline predictive of a complication. Patients with a serum creatinine > or = 5.0 mg/dl were 2.3 times as likely to have a complication (odds ratio, 2.3; 95% confidence interval, 1.3 to 4.1; P < 0.005). Complications were identified in 38 (42%) patients by < or = 4 h, in 61 (67%) patients by < or = 8 h, in 77 (85%) patients by < or = 12 h, and in 81 (89%) patients at < or = 24 h. The PRB remains a safe procedure, but the risk of complication is higher in patients with advanced renal insufficiency. After biopsy, an observation time of up to 24 h remains optimal as an observation period of < or = 8 h risks missing > or = 33% of complications.

PMID:
14694166
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center